Skip to main content
Non-Coding RNA logoLink to Non-Coding RNA
. 2022 Nov 21;8(6):79. doi: 10.3390/ncrna8060079

Correction: Tusup et al. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA 2021, 7, 5

Marina Tusup 1,2, Phil F Cheng 1,2, Ernesto Picardi 3,4, Austeja Raziunaite 1,2, Reinhard Dummer 1,2, Mitchell P Levesque 1,2, Lars E French 1,2,5, Emmanuella Guenova 1,2,6, Thomas M Kundig 1,2, Steve Pascolo 1,2,*
PMCID: PMC9680213  PMID: 36412914

In the original article [1], there were two mistakes in the published version of Table 1. For patient 3, the tumor should be “Metastasis” instead of “Primary”; for patient 10, the excision place should be “Lymph Node” instead of “Skin”. The corrected Table 1 appears below.

Table 1.

Patients and corresponding cell lines. The table presents the patients’ demographics and treatments as well as the characteristics of the cell lines.

Gender Tumor Excision Place Cell Lines Treatment Immunotherapy Duration Cell Line Purity
Patient 1 M Metastasis Lymph node MM130820 Before IT 87%
Patient 2 F Metastasis Trunk MM150325 Before IT 98%
F Metastasis Trunk MM150604 Relapsed Ipilimumab 3 weeks 74%
Patient 3 F Metastasis Lymph node MM140905 Before IT 99%
Patient 4 M Metastasis Back M130107 Before IT 59%
M Metastasis Lymph node M121102 Before IT 65%
Patient 5 F Metastasis Lung M121008 Before IT 20%
Patient 6 F Metastasis Lymph node MM130626 Before IT 60%
Patient 7 F Metastasis Leg MM130106 Before IT 57%
F Metastasis Leg MM131205 Relapsed Ipilimumab 3 weeks 78%
F Metastasis Leg MM131206 Relapsed Ipilimumab 3 weeks 65%
Patient 8 M Metastasis Trunk MM150405 Before IT 58%
M Metastasis Lymph node M150404 Before IT
Patient 9 F Metastasis Skin MM130926 Before IT 50%
Patient 10 F Metastasis Lymph node M980513 Before IT 83%
Patient 11 M Metastasis Arm MM140902 Relapsed Ipilimumab 3 months 100%
M Metastasis Arm M130830 Relapsed Ipilimumab 3 months 100%
Patient 12 M Metastasis Back MM130434 Relapsed Ipilimumab 3 months 77%
Patient 13 M Metastasis Trunk MM121224 Relapsed Ipilimumab 3 months 75%
Patient 14 M Metastasis Skin M130420 Relapsed Ipilimumab 10 days 100%
M Metastasis Liver M130421 Relapsed Ipilimumab 10 days 100%
M Metastasis Testis M130425 Relapsed Ipilimumab 10 days 100%
M Metastasis Lung MM130427 Relapsed Ipilimumab 10 days 97%

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Tusup M., Cheng P.F., Picardi E., Raziunaite A., Dummer R., Levesque M.P., French L.E., Guenova E., Kundig T.M., Pascolo S. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA. 2021;7:5. doi: 10.3390/ncrna7010005. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Non-Coding RNA are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES